Durham University

Monroe Capital Hires Waleed Noor as Head of Middle East and Plans to Open Abu Dhabi Office

Retrieved on: 
Wednesday, March 20, 2024
Professional Services, Other Professional Services, Finance, Construction & Property, Asset Management, REIT, Banque Saudi Fransi, Commerzbank, Risk management, Goldman Sachs, Crédit Agricole, Durham University, Capital, MEA, Nottingham University Business School

Monroe Capital LLC (“Monroe”) today announced it has expanded its platform to the Middle East with the appointment of Waleed Noor as Managing Director and Head of Middle East Distribution.

Key Points: 
  • Monroe Capital LLC (“Monroe”) today announced it has expanded its platform to the Middle East with the appointment of Waleed Noor as Managing Director and Head of Middle East Distribution.
  • Monroe is in the process of opening an office in Abu Dhabi.
  • Mr. Noor will be based in Abu Dhabi and be responsible for representing Monroe throughout the region.
  • We look forward to our continued strategic growth and expansion in the Middle East,” said Ted Koenig, Chairman and CEO of Monroe Capital.

Alpine Investors Names Mark Strauch as President and Promotes Three to Partner and Four to Principal

Retrieved on: 
Tuesday, January 30, 2024
Professional Services, Finance, ASG, Growth, Yale University, University, Organizational culture, Mathematics, Playbook, Computer science, Psychology, Marketing, Stanford University, Investment, Durham University, Partner, Acquisition, Brown University, Software as a service, Princeton University, Software, Entrepreneurship, Management

Alpine Investors (“Alpine”), a Certified B Corp people-driven private equity firm committed to building enduring software and services companies, has announced Mark Strauch as President and promoted three professionals to Partner and four professionals to Principal.

Key Points: 
  • Alpine Investors (“Alpine”), a Certified B Corp people-driven private equity firm committed to building enduring software and services companies, has announced Mark Strauch as President and promoted three professionals to Partner and four professionals to Principal.
  • Mark Strauch, a Founding Partner and co-leader of the firm’s Investing team, has been named Alpine’s President.
  • Mark also is a co-founder and chairman of Alpine Software Group (ASG) , the firm's affiliate software platform that buys, builds, and operates vertical SaaS businesses.
  • Since joining Alpine, Haley has closed more than 30 deals and served on the board of six Alpine portfolio companies.

Genomics plc publishes clinical trial results demonstrating successful integration and clinical utility of integrated risk scores combining polygenic and clinical risk of cardiovascular disease in NHS primary care

Retrieved on: 
Wednesday, January 31, 2024
NHS health check, GP, CVD, Cholesterol, Genetics, Knowledge, Family, IRT, Heart, FRS, Cardiovascular disease, Clinical trial, Risk assessment, BMI, Patient, Ageing, Friends, Durham University, NHS, European Journal, Risk, PRS, National Health Service, Blood pressure, Absolute risk

The HEART Study is the world's first clinical trial investigating the use of genomic 'polygenic risk score (PRS) testing' to support the prevention of cardiovascular disease (CVD) in National Health Service (NHS) clinical practice.

Key Points: 
  • The HEART Study is the world's first clinical trial investigating the use of genomic 'polygenic risk score (PRS) testing' to support the prevention of cardiovascular disease (CVD) in National Health Service (NHS) clinical practice.
  • It was designed to evaluate an integrated risk tool (IRT) that combines genetic risk in the form of a polygenic risk score or PRS, with QRISK, a prediction algorithm for CVD.
  • For people aged 45-64, genetics accounts for 40% as much risk as all the non-genetic risk factors combined in QRISK.
  • We hope that it will also encourage similar studies incorporating genetics into clinical risk prediction for other common diseases."

Actio Biosciences Appoints Samuel Collins, MBBS, Ph.D., MBA, as Chief Medical Officer as Company Advances Multiple Precision Medicine Programs Toward Clinical Development

Retrieved on: 
Wednesday, January 24, 2024
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, TRPV4, Patient, Therapy, Biology, Pediatrics, University, Drug discovery, Pfizer, MBA, IND, Acquisition, Durham University, Medicine, MBBS, University college, Pharmaceutical industry

He brings nearly 20 years of experience spanning academia and industry, with a focus in rare disease and pediatrics.

Key Points: 
  • He brings nearly 20 years of experience spanning academia and industry, with a focus in rare disease and pediatrics.
  • “We are thrilled to welcome Sam to the Actio team at this important time in our company’s evolution,” said David Goldstein, Ph.D., co-founder and CEO of Actio.
  • “Sam brings a deep understanding of clinical development, supported by years working in rare disease research, including as a treating physician.
  • He served as medical director of Therachon AG, prior to its 2019 acquisition by Pfizer, and before that, was medical director at Premier Research.

New Holland Promotes Three to Managing Director

Retrieved on: 
Thursday, January 4, 2024
UBS, Columbia University, Growth, ISAM, Investment, Mathematics, Conner, Economics, Durham University, Princeton University, Portfolio, Ludacris, Harvard University, Management

NEW YORK, Jan. 4, 2024 /PRNewswire/ -- New Holland Capital, an alternative asset manager, today announced that Portfolio Managers Andrew Parchman, Chris Bridges and Conner Murphy have been promoted to Managing Director, effective immediately.

Key Points: 
  • NEW YORK, Jan. 4, 2024 /PRNewswire/ -- New Holland Capital, an alternative asset manager, today announced that Portfolio Managers Andrew Parchman, Chris Bridges and Conner Murphy have been promoted to Managing Director, effective immediately.
  • New Holland Capital CEO Scott Radke said: "We're incredibly excited to recognize the promotions of Andy, Chris and Conner.
  • Chris Bridges joined New Holland in 2016 after starting his career at systematic hedge fund ISAM.
  • Conner Murphy started his career at New Holland as an intern before joining as an analyst in 2013.

Global Ship Lease Announces CEO Transition

Retrieved on: 
Thursday, December 7, 2023
Poseidon, GSL, MBA, Durham University, Management

George Youroukos, Executive Chairman of Global Ship Lease, commented, “Over the last 16 years as CEO of Global Ship Lease, Ian oversaw the Company’s listing on the NYSE in 2008, guided it safely through the most challenging period the containership industry has ever experienced, and was fully committed to ensuring that the transformative merger with Poseidon Containers in 2018 was a success.

Key Points: 
  • George Youroukos, Executive Chairman of Global Ship Lease, commented, “Over the last 16 years as CEO of Global Ship Lease, Ian oversaw the Company’s listing on the NYSE in 2008, guided it safely through the most challenging period the containership industry has ever experienced, and was fully committed to ensuring that the transformative merger with Poseidon Containers in 2018 was a success.
  • Global Ship Lease has become a larger, stronger, and more valuable company on his watch.
  • He has led our strategic and commercial response to the growing pressures on the industry to decarbonize and is very well-qualified to take Global Ship Lease forward at this time of increasingly rapid change.”
    Thomas Lister commented, “I feel very privileged to become CEO of Global Ship Lease and, having worked closely with Ian for 16 years, and with George, Tassos, and the rest of the team since 2018, I am confident that the transition will be a smooth one.
  • With the support of our excellent teams at sea, on shore, and in the boardroom, this is an exciting time to be taking the reins at Global Ship Lease.”
    For more information on Global Ship Lease, please visit www.globalshiplease.com .

Parker Moss to Join Exscientia as EVP, Corporate Development

Retrieved on: 
Tuesday, October 17, 2023
Technology, Human Resources, Health Technology, Professional Services, Software, Biotechnology, Pharmaceutical, Health, Oncology, Artificial Intelligence, Social work, Partnership, Medicine, Fidelity, Philosophy, Genomics England, VC, Great Ormond Street Hospital, AI, Whole genome sequencing, State, Hospital, Cancer, Genomics, Natural science, NHS, 100,000 Genomes Project, Virgin Care, Corporate development, Cancer Research UK, Durham University, Management, Pharmaceutical industry, Parker, Physics

Exscientia plc (Nasdaq: EXAI) today announced the appointment of Parker Moss as Executive Vice President, Corporate Development, effective January, 2024.

Key Points: 
  • Exscientia plc (Nasdaq: EXAI) today announced the appointment of Parker Moss as Executive Vice President, Corporate Development, effective January, 2024.
  • In this newly established role, Parker will lead the creation and execution of a focused corporate development strategy to strengthen further and create new market opportunities for the company’s precision medicine, clinical and tech innovation platforms, with a particular focus on oncology.
  • Parker is also the co-lead of Genomics England’s research programme in cancer and rare disease.
  • Parker also holds several non-executive roles, including on the Cancer Research Horizons board (a company wholly owned by Cancer Research UK).

Durham University Implements CoolIT's Direct Liquid Cooling Technology in the Cosmology Machine-8 Supercomputer

Retrieved on: 
Friday, October 13, 2023
National Infrastructure Commission, MP, Science and Technology Facilities Council, Knowledge, ICC, Business, ESG, Dell, Newcastle upon Tyne Central (UK Parliament constituency), Original equipment manufacturer, Memory, Group Policy, AB, Astronomy, Digital, DiRAC, Cosmology, Institute for Computational Cosmology, Data, DLC, UKRI, Biophysical environment, Science, Durham University, Water, Physics, Renewable energy, Social

CALGARY, AB and DURHAM, United Kingdom, Oct. 13, 2023 /PRNewswire-PRWeb/ -- The Institute for Computational Cosmology (ICC) at Durham University has officially inaugurated the Cosmology Machine-8 (COSMA-8) supercomputer on Friday, 13th October. This remarkable infrastructure, part of the National Infrastructure DiRAC facility (DiRAC) https://dirac.ac.uk/ incorporates CoolIT's state-of-the-art Direct Liquid Cooling (DLC) technology, making it one of the largest supercomputers in the UK committed to pioneering scientific exploration.

Key Points: 
  • CALGARY, AB and DURHAM, United Kingdom, Oct. 13, 2023 /PRNewswire-PRWeb/ -- The Institute for Computational Cosmology (ICC) at Durham University has officially inaugurated the Cosmology Machine-8 (COSMA-8) supercomputer on Friday, 13th October.
  • This remarkable infrastructure, part of the National Infrastructure DiRAC facility (DiRAC) https://dirac.ac.uk/ incorporates CoolIT's state-of-the-art Direct Liquid Cooling (DLC) technology, making it one of the largest supercomputers in the UK committed to pioneering scientific exploration.
  • Hosted by the Institute for Computational Cosmology at Durham University on behalf of the DiRAC HPC facility, COSMA 8 is set to take center stage as part of the DiRAC Memory Intensive service.
  • Dominik Dziarczykowski, CoolIT's Global Channel Sales Manager, expressed, "Collaborating with Durham University and DiRAC on the COSMA-8 project exemplifies the efficiency, scalability, and transformative potential of Direct Liquid Cooling.

Neuronic Welcomes Light Therapy Experts to its Scientific Advisory Board

Retrieved on: 
Thursday, August 31, 2023
Lymphedema, University, Delirium, Coronavirus Scientific Advisory Board, Human, Research, Nanomedicine, Brain, Federation of European Pharmacological Societies, Inflammation, Biomarker, Associate, Bachelor of Science, World Association for Medical Law, BPS, Harvard Medical School, CTE, Low-level laser therapy, Alzheimer's disease, Parkinson's disease, Publication, ARCS, COVID-19, Tissue engineering, Laser, Pain management, PBM, Allied health professions, EGG, British Pharmacological Society, WALT, Post-concussion syndrome, University of Johannesburg, Chronic pain, ALS, Distinguishing, Durham University, Pharmaceutical industry, Nursing, Cholinergic neuron, Honours degree, Dermatology, Doctor of Philosophy, Medicine

EGG HARBOR, N.J, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Neuronic, a pioneering company in the field of photobiomodulation (PBM) technology, also known as light therapy, is proud to announce the addition of three distinguished individuals to its Scientific Advisory Board.

Key Points: 
  • EGG HARBOR, N.J, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Neuronic , a pioneering company in the field of photobiomodulation (PBM) technology, also known as light therapy, is proud to announce the addition of three distinguished individuals to its Scientific Advisory Board.
  • These esteemed individuals, collectively joining Neuronic's Scientific Advisory Board , underscore the company's commitment to advancing the frontiers of photobiomodulation.
  • "Our new Scientific Advisory Board members symbolize the excellence and innovation we strive for at Neuronic," said Liam Pingree , co-founder of Neuronic.
  • "We are thrilled to welcome these distinguished experts who share our vision and passion for enhancing brain wellness through photobiomodulation."

Oxford Science Enterprises Appoints Ed Bussey as Chief Executive Officer

Retrieved on: 
Thursday, August 31, 2023
Ed Bussey, Heart, University of Oxford, Partnership, Natural science, University, CFA, Eating disorder, Marketing, Cancer, EBay, MBA, Royal Navy, McKinsey & Company, Sale, Oxford Sciences Enterprises, Retinal, Antibody, Jellyfish, Commander of the Navy (Sri Lanka), Growth, CIO, Merrill (company), OSE, Durham University, BA, Management, Cryptocurrency, Quill

OSE introduces Chief Investment Officer role, appointing Jack Edmondson

Key Points: 
  • OSE introduces Chief Investment Officer role, appointing Jack Edmondson
    Oxford, UK: August 31, 2023: Oxford Science Enterprises (OSE), the independent investment company created to found, fund and build transformational businesses via its unique partnership with the University of Oxford, today announces the appointment of Ed Bussey as CEO and Jack Edmondson as CIO.
  • We are delighted by the appointments of Ed and Jack,” said Chris Chambers, Chairman of Oxford Science Enterprises.
  • ​​“The University of Oxford is home to the world’s leading scientific research and the opportunity this presents to build businesses that can solve the world’s most pressing challenges is one I could not refuse,” said Ed Bussey, CEO, Oxford Science Enterprises.
  • Oxford Science Enterprises has established itself as the leading investor in university spinouts in the UK and raised £850 million from blue-chip international investors.